Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of encorafenib + binimetinib + cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer
2018-000271-32Phase 2Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of encorafenib, binimetinib and cetuximab in colorectal cancer (CRC), sponsored by Pierre Fabre Laboratories. Primary endpoint: Confirmed overall response rate (cORR) by local review. Started Jul 2018; status: completed.
02
Drugs
encorafenibbinimetinibcetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2018-000271-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000271-32.